Big news for dealing with coronavirus and for the healthcare and life sciences sector in Catalonia: pharmaceutical company Reig Jofre, a member of CataloniaBio & HealthTech, has reached a deal with Janssen of Johnson & Johnson to manufacture its Covid-19 vaccine in Phase III clinical trials.

Reig Jofre has extensive experience in manufacturing injectable and freeze-dried products, both its own and for third parties. In the first quarter of 2021, the company will launch a new state-of-the-art plant in Sant Joan Despí (Barcelona) that will help meet the need for fast, secure deployment of the Covid-19 vaccine. The pharmaceutical company will be able to manufacture 250 million dosages a year. The vaccine will be distributed by Janssen.

Ignasi Biosca, CEO of Reig Jofre and former president of CataloniaBio & HealthTech (2014-2018), explains, “We are proud to see that Reig Jofre’s sustained effort investing in technology and industrial capabilities will now be decisive in deploying the Covid-19 vaccine in many countries.”

Biosca also highlights the importance of having been chosen by Janssen as one of its partners: “It will give us the opportunity to demonstrate the strategic value of having a strong, competitive, technologically advanced industry to overcome a critical situation like this one.”

More information

You may also be interested in:

• Reig Jofre, ready to produce the vaccine for Covid-19
• Reig Jofre begins a clinical study of a food supplement to reduce the incidence of Covid-19